ES2974307T3 - PERM como marcador de cáncer de endometrio - Google Patents

PERM como marcador de cáncer de endometrio Download PDF

Info

Publication number
ES2974307T3
ES2974307T3 ES17713973T ES17713973T ES2974307T3 ES 2974307 T3 ES2974307 T3 ES 2974307T3 ES 17713973 T ES17713973 T ES 17713973T ES 17713973 T ES17713973 T ES 17713973T ES 2974307 T3 ES2974307 T3 ES 2974307T3
Authority
ES
Spain
Prior art keywords
perm
mmp9
kpym
ldha
nampt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17713973T
Other languages
English (en)
Spanish (es)
Inventor
Garcia Elena Martinez
Ortega Eva Colas
Moreno Antonio Gil
Puigjaner Jaume Reventos
Bruno Domon
Antoine Lesur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fundacio Institut de Recerca Hospital Universitari Vall dHebron
Original Assignee
Fundacio Institut de Recerca Hospital Universitari Vall dHebron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Institut de Recerca Hospital Universitari Vall dHebron filed Critical Fundacio Institut de Recerca Hospital Universitari Vall dHebron
Application granted granted Critical
Publication of ES2974307T3 publication Critical patent/ES2974307T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57442—Specifically defined cancers of the uterus and endometrial
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/908—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
    • G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES17713973T 2016-05-04 2017-03-30 PERM como marcador de cáncer de endometrio Active ES2974307T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16168328 2016-05-04
PCT/EP2017/057635 WO2017190896A1 (en) 2016-05-04 2017-03-30 Mmp9 as marker of endometrial cancer

Publications (1)

Publication Number Publication Date
ES2974307T3 true ES2974307T3 (es) 2024-06-26

Family

ID=56096908

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17713973T Active ES2974307T3 (es) 2016-05-04 2017-03-30 PERM como marcador de cáncer de endometrio

Country Status (12)

Country Link
US (2) US20190137499A1 (enExample)
EP (3) EP4610655A3 (enExample)
JP (3) JP7240712B2 (enExample)
AU (3) AU2017260806B9 (enExample)
BR (1) BR112018072498A2 (enExample)
CA (2) CA3286798A1 (enExample)
DK (1) DK3452829T3 (enExample)
ES (1) ES2974307T3 (enExample)
FI (1) FI3452829T3 (enExample)
PL (1) PL3452829T3 (enExample)
PT (1) PT3452829T (enExample)
WO (1) WO2017190896A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7421218B2 (ja) * 2017-07-21 2024-01-24 フンダシオ オスピタル ウニベルシタリ バル デブロン－インスティテュート デ レセルカ 子宮内膜癌のマーカとしてのａｇｒｉｎ
CN118556133A (zh) 2021-07-23 2024-08-27 瓦尔德西布伦大学医院基金会研究所 子宫内膜癌的生物标记物
CN113493838B (zh) * 2021-09-06 2021-11-23 北京泱深生物信息技术有限公司 子宫内膜癌相关的标志分子及其在诊断子宫内膜癌中的应用
KR102640230B1 (ko) * 2021-09-24 2024-02-22 가천대학교 산학협력단 C-peptide를 처리한 자궁내막 기질세포의 이동성 변화 기작을 이용한 자궁내막 관련질환의 진단 방법 및 자궁내막 관련질환 치료제의 스크리닝 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444879A (en) * 1981-01-29 1984-04-24 Science Research Center, Inc. Immunoassay with article having support film and immunological counterpart of analyte
AUPO573697A0 (en) * 1997-03-20 1997-04-10 Prince Henry's Institute Of Medical Research Diagnosis of endometrial cancer
US20080226554A1 (en) * 2003-12-23 2008-09-18 Mount Sinai Hospital Methods For Detecting Markers Associated With Endometrial Disease or Phase
WO2008003024A2 (en) * 2006-06-28 2008-01-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Method and composition for diagnosing endometrial cancer
WO2008049239A1 (en) * 2006-10-27 2008-05-02 Mount Sinai Hospital Endometrial biomarkers
CN102549169B (zh) * 2009-07-24 2016-02-24 吉第克生物技术有限公司 子宫内膜癌的标记物

Also Published As

Publication number Publication date
EP4180814A2 (en) 2023-05-17
JP2023040246A (ja) 2023-03-22
AU2017260806B9 (en) 2023-07-20
AU2017260806B2 (en) 2023-06-15
JP7492287B2 (ja) 2024-05-29
PL3452829T3 (pl) 2024-05-20
AU2017260806A1 (en) 2018-12-13
EP3452829B1 (en) 2024-01-24
WO2017190896A1 (en) 2017-11-09
US20190137499A1 (en) 2019-05-09
EP4610655A2 (en) 2025-09-03
AU2023210591B2 (en) 2025-06-26
JP7240712B2 (ja) 2023-03-16
BR112018072498A2 (pt) 2019-03-12
EP4610655A3 (en) 2025-12-10
EP3452829A1 (en) 2019-03-13
DK3452829T3 (da) 2024-03-25
US20230221323A1 (en) 2023-07-13
CA3022586A1 (en) 2017-11-09
AU2025223935A1 (en) 2025-09-18
CA3286798A1 (en) 2025-10-30
JP2019516104A (ja) 2019-06-13
EP4180814A3 (en) 2023-07-12
AU2023210591A1 (en) 2023-08-24
AU2023210591B9 (en) 2025-07-10
FI3452829T3 (fi) 2024-03-20
JP2024116127A (ja) 2024-08-27
PT3452829T (pt) 2024-03-22

Similar Documents

Publication Publication Date Title
Bagaria et al. Comparative study of CEA and CA19-9 in esophageal, gastric and colon cancers individually and in combination (ROC curve analysis)
Shimura et al. Urinary ADAM12 and MMP-9/NGAL complex detect the presence of gastric cancer
US10509034B2 (en) Bladder carcinoma biomarkers
JP2009527735A (ja) 癌に対するバイオマーカーとしての遊離ｎｇａｌ
AU2023210591B9 (en) Markers of endometrial cancer
US20240011994A1 (en) Ctnb1 as a marker for endometrial cancer
US20220244261A1 (en) Method for diagnosing colorectal cancer
CN103913575B (zh) 半胱氨酸蛋白酶抑制剂s与糖类抗原19-9的联合应用
BR122025014970A2 (pt) Método e uso que compreendem kpym para o diagnóstico ou prognóstico de carcinoma endometrial, bem como kit para detectar o nível de expressão de kpym e outros marcadores
BR122023026792A2 (pt) Método e uso da combinação dos marcadores perm e clic1 como marcadores in vitro para diagnosticar ou prognosticar carcinoma endometrial, bem como kit para detectar nível de expressão proteica
BR122024027006A2 (pt) Método para o diagnóstico de câncer endometrial em uma amostra de fluido uterino, kit e método implementado por computador para realizar o dito método diagnóstico e método para decidir ou recomendar um regime médico